Lion’s Mane: Cognition, Mood, Preparations and Safety Evidence

Table of contents

• Evidence summary
• What Lion’s Mane is
• Preparations and formats
• Proposed mechanisms
• The hype vs the evidence
• Benefits by claim
• Claims and limits
• Safety reports and gaps
• Medicines and evidence gaps
• Who should seek advice first
• Studied protocols
• How preclinical findings are used
• Funding, conflicts and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary

Claim	Evidence	Source	Funding/conflict	Strength
Cognitive scores in older adults with MCI	30 randomized, 29 analysed; modified HDS-R-based scale favoured treatment at several timepoints. Scores declined after stopping but remained above placebo at follow-up	Mori original	Four Hokuto-affiliated authors; company grew fruit bodies; cash and supply terms not itemised	Small selected trial; no dementia-prevention or general memory proof
Depression and mood complaints	30 women enrolled, 26 analyzed, four weeks. Total CES-D and ICI changes did not differ significantly between groups; two individual complaint items favored treatment	Nagano 2010, full paper	Aso Biotech supplied cookies; two authors had company affiliations	Insufficient for a depression-treatment claim
Cognition and stress in young adults	43 acute/41 chronic participants; 1.8 g/day. Exploratory Stroop interaction p=0.027; within-treatment change p=0.005. Stress findings varied by analysis; global cognition did not improve consistently	Docherty 2023	Sempera Organics supplied active and placebo products; no additional external funding	Weak; company supplied
Human nerve regeneration / NGF stimulation	Preclinical hypothesis, without demonstrated clinical nerve regeneration	Chong 2019, mechanism review	Review of laboratory and animal mechanisms; not a human intervention trial	Insufficient

What Lion’s Mane is

Lion’s Mane, also called Yamabushitake, is an edible mushroom. Its fruiting body and cultured mycelium are different fungal materials, and research uses powders, specified mycelial preparations, proprietary complexes and extracts (review background/composition; mycelial protocol; pilot preparation; fruiting-body extract protocol). A market label does not identify which of those preparations has been tested.

Products may contain fruiting-body powder, mycelium, extracts or mixtures. Hericenones and erinacines are associated with different fungal materials, but amounts depend on cultivation and processing. Trial formulations and doses vary and cannot be assumed equivalent (Chong 2019, mechanism review).

Preparations and formats

Form	What it is	Typical marker compound	Standardization reality	Notes
Fruiting-body powders and extracts	Powdered reproductive fungal material or a specified extract	Hericenones and other constituents; content depends on preparation	Do not infer a measured potency or clinical equivalence from the name	Mori used powder in tablets and Nagano powder in cookies, not interchangeable generic extracts (Mori; Nagano)
Mycelial preparations	Vegetative fungal biomass; cultivation and retained substrate differ	Erinacines occur mainly in mycelia; not a universal assay	Do not assume all mycelial products are grain residues or low biomass	The 2019 AESAN consultation classified the assessed dehydrated mycelium powder as novel food because pre-May 1997 EU consumption history was not established; this is not a toxicity finding (original decision). Li used a specified submerged-culture preparation (Methods)
Mixed materials and dual-solvent extraction	A fruiting-body/mycelium mixture differs from using two extraction solvents	Composition depends on the identified preparation	“Dual extract” alone does not specify a fungal-material ratio	The review describes an 80:20 mycelium/fruiting-body clinical preparation; Surendran used water/ethanol extraction of fruiting body alone. Neither establishes a universally best blend or form (clinical/composition review; original Methods)
Capsules and tablets	A delivery format for a specified material	Depends on capsule/tablet contents	Format alone does not establish potency	Mori tested twelve 250 mg tablets daily at 96% powder; Docherty used three 600 mg capsules of a proprietary complex (Mori Methods; Docherty Methods)
Liquids and retail tinctures	A beverage made with an extract differs from a tincture	Depends on extraction and measured contents	No retail tincture equivalence follows from a drink protocol	An acute trial tested 3 g fruiting-body extract in a 250 mL lemon/water drink; this does not establish efficacy or equivalence of every liquid (Surendran Methods/Results)
Food-based (cookies, coffee blends)	Powder incorporated into food/drink	Fruiting-body powder	Dose-controlled only in research settings	Nagano 2010 used four cookies daily, each containing 0.5 g powder: 2 g/day

Proposed mechanisms

Hericenones and erinacines are among the compounds discussed in NGF-related cell and animal research (composition/mechanism review). Reports about absorption or brain entry in other species do not establish delivery, NGF stimulation or nerve repair in a living human brain after a retail supplement. The original MCI trial itself described that mechanism as unresolved (original Discussion).

NGF hypotheses largely come from cells and animals (mechanism review); they do not demonstrate human nerve regeneration. The separately cited 2025 paper tested specified mushroom powders in animal toxicity and bacterial/mouse genotoxicity assays, not human cognitive efficacy (original Methods).

The hype vs the evidence

The studies below use different formulations, populations and endpoints. A task-specific improvement, a within-group change or an animal pathway is insufficient to establish a dependable “brain fog cure” or general nootropic effect.

• The MCI trial randomized 30 adults aged 50–80; 29 were analysed after one active participant withdrew with stomach discomfort. Four 250 mg tablets containing 96% fruiting-body powder were taken three times daily for 16 weeks: 3 g tablets, equivalent to 2.88 g powder per day. A modified HDS-R-based scale favoured treatment at weeks 8, 12 and 16 and at the four-week follow-up. Scores nevertheless declined after stopping; this did not measure nerve regeneration or establish dementia prevention (original Methods/Results).
• Mood trial: 30 women enrolled and 26 were analyzed. Four cookies supplied 2 g/day for four weeks. Depression scores improved within treatment, but the change did not significantly exceed placebo; two complaint items favored treatment (Nagano 2010, full paper).
• Young-adult pilot: 43 participants contributed acute data and 41 chronic data. The Stroop treatment-by-time interaction was significant; p=0.005 referred to the treatment group’s before/after change. Stress VAS findings were exploratory: treatment effect p=0.051, with a planned day-29 comparison p=0.033, while perceived-stress-scale results were null. Memory results included unfavorable findings (Docherty 2023).

Trials are small, use different preparations and report inconsistent outcomes. Commercial ties include company affiliations or supplied products. These studies do not establish a dependable “brain fog cure” or routine cognitive benefit for supplement users.

Benefits by claim

Memory and general cognition

Mori’s small MCI trial used a modified HDS-R-based scale (original). Saitsu randomized 34 healthy adults over 50 and analysed 31 after exclusions. At 12 weeks, MMSE was 30.00 versus 29.53 (p=0.0328), while visual-retention and paired-associate tests were null; the age-adjusted interaction was significant. The near-ceiling scale and small multiple-endpoint experiment do not establish dementia prevention or general memory enhancement (original Methods/Tables).

Mood, stress, and “brain fog”

The mood trial did not show a significant between-group difference in total depression scores (Nagano 2010, full paper). The young-adult pilot reported mixed, exploratory stress findings (Docherty 2023). Neither establishes a treatment for depression or a validated “brain fog” outcome.

Focus and reaction time

Docherty’s 2023 pilot found an exploratory Stroop signal alongside null global performance and unfavourable memory results (original Results). The 2025 crossover trial in 18 young adults had null global cognition and mood composites. Dominant-hand pegboard performance favoured its fruiting-body-extract drink, but Flanker performance after the drink was worse than control, and other findings were mixed (original Results). Neither establishes reliable general focus enhancement.

Nerve regeneration / neuroprotection

Cell and animal NGF findings are research hypotheses (mechanism review), not proof of human nerve regeneration. The 49-week trial’s biomarker/MRI observations also did not demonstrate nerve repair: several findings were within-group and not significant between groups (original Tables/Discussion). Animal toxicity assays address a different question (original Methods).

Claims and limits

Claim	Verdict	Basis
Cognitive score signal in MCI	Limited short-term signal in a small selected sample	Modified-scale scores declined after stopping but remained higher than placebo at follow-up; no dementia prevention endpoint (original Results)
Treats depression or anxiety	Not established	Total depression and complaint-index changes did not significantly exceed placebo in the small four-week trial (Nagano 2010, full paper)
“Brain fog cure” / general nootropic for healthy adults	Not supported	Company-supplied pilot showed mixed results without consistent global cognitive benefit (Docherty 2023)
Nerve regeneration or rebuilding damaged nerves	Not established by the reviewed human outcomes	Cell/animal NGF hypotheses and limited human biomarkers do not demonstrate nerve repair (review; original human Results)
Safety across products and populations	Not established by small selected trials	Mori had mild GI reports in both arms and one active withdrawal; Li reported three active and one placebo AE withdrawal (Mori; Li). A severe probable oral-extract case is separate (original case)

Safety reports and gaps

Side effect	Frequency	Notes
Digestive symptoms	Observed in small selected studies; general incidence unknown	Mori reported mild stomach discomfort/diarrhoea in seven active and six placebo participants, with one active withdrawal. Li had active digestive-symptom withdrawals (Mori safety; Li Results)
Skin rash	Reported during the specific mycelial trial; population frequency unknown	Rash was among the reasons for active-group withdrawal in Li; this is not proof of universal contact-allergy incidence (original adverse events)
Severe respiratory injury after oral extract use	Single probable case; frequency not determined	A 63-year-old man developed ARDS after months of oral extract use and required mechanical ventilation. Authors judged the reaction probable rather than definite; this was not occupational inhalation (complete original case)
Menstrual bleeding report	One participant excluded; group and causation not established	Nagano excluded one woman who reported an 18-day menstrual period; it did not establish that the supplement caused it (original Results)
Serious harms and laboratory tests	Small trials cannot establish absence of rare/severe effects	Mori found no clinically meaningful laboratory harm, alongside mild GI reports. The separate probable ARDS case demonstrates why laboratory reassurance is not all-user clearance (Mori Results; original case)

Li’s 49-week pilot tested a specified erinacine-A-enriched mycelial preparation in people with mild Alzheimer’s disease: 49 randomized, 41 completed. Four withdrew for adverse events—three active participants with abdominal discomfort, nausea or rash, and one placebo participant with nausea. Final CASI/MMSE between-group comparisons were not significant, while IADL favoured treatment; numerous outcomes and the small completer analysis limit inference. This is neither dementia-prevention proof nor all-product long-term safety clearance (original Methods/Results/Tables).

Medicines and evidence gaps

Medicine/context	What was studied	Practical boundary	Evidence basis
Glucose-lowering medicines	The reviewed cognition/mood protocols did not quantify a clinical glucose-drug interaction	Ask about the exact supplement and medicines; no measured additive-hypoglycaemia risk follows from these trials	The 2025 trial excluded diabetes and relevant regular medicines (original eligibility)
Anticoagulants and antiplatelets	These trials did not test bleeding risk with warfarin, DOACs or antiplatelet combinations	A proposed constituent or general-mushroom effect is not an established clinical interaction	The 2025 protocol excluded bleeding disorders and many regular medicines; no bleeding-drug endpoint (Methods)
Immunosuppressants	No immune-drug interaction outcome was measured in the reviewed protocols	Do not infer safety or a confirmed interaction from cell/animal immune pathways	The 2025 trial excluded autoimmune conditions and regular medicines; cognition/mood were endpoints (Methods)
Other medicines	Selected cognition/mood studies are not comprehensive pharmacokinetic interaction tests	Review the exact combination with a clinician/pharmacist	Docherty restricted prescription medicines with exceptions, and its outcomes were cognition/mood (original Methods/supplement)

The medication statements above describe gaps in the reviewed protocols, not measured rates of interaction or a settled all-product safety profile. Selected eligibility rules and cognitive/mood endpoints cannot establish every combination’s pharmacokinetics or harms (pilot protocol; crossover protocol). Do not change prescribed treatment based on an untested supplement combination.

Who should seek advice first

• People with previous mushroom reactions or new breathing/skin symptoms should seek medical advice. The severe oral-extract report is a single probable case, not an incidence estimate or proof that every mushroom allergy cross-reacts with every Lion’s Mane product (original respiratory case).
• Pregnancy and breastfeeding: the selected reviewed studies do not establish safety, and the young-adult/healthy-older-adult protocols excluded these situations (supplement eligibility; Methods; Methods). Seek individual advice rather than extrapolating from other populations.
• People taking regular medicines: the reviewed protocols did not measure the combinations listed above. Discuss the exact medicine and product; theoretical biological effects are not quantified clinical interactions or safety clearance (protocol; protocol).
• People with memory decline or depression should seek clinical assessment. These small studies did not demonstrate a generally reliable replacement for established care (selected MCI trial; mood trial; mild-AD pilot).
• When assessing a product, distinguish its fungal material, processing, quantities and measured constituents. An erinacine assay for Li’s mycelia, Mori’s fruiting-body powder and a proprietary mushroom complex describe different preparations (Methods; Methods; Methods). Those examples do not establish widespread adulteration or a required retail potency standard.

Studied protocols

Context	Dose used in trials	Duration	Source
MCI, selected adults aged 50–80	Four 250 mg tablets containing 96% fruiting-body powder, three times daily: 3 g tablets/2.88 g powder daily	16 weeks plus 4-week follow-up	Mori original
Mood/complaint trial	Four cookies × 0.5 g powder = 2 g/day	Four weeks	Nagano 2010, full paper
Young-adult cognition/stress pilot	Three 600 mg SO-DSX1 capsules: 1.8 g/day proprietary mushroom complex	Single-dose assessment and 28 days	Docherty original

These are study protocols, not a confirmed optimal dose or a complete human-trial census. Other preparations discussed here include 3.2 g/day fruiting-body powder for 12 weeks, a single 3 g fruiting-body-extract drink and 1.05 g/day specified mycelia for 49 weeks (Saitsu; Surendran; Li). Different extracts and quantities cannot be assumed equivalent; no broad retail-adulteration rate follows from this evidence.

How preclinical findings are used

Cell and animal studies can suggest mechanisms or assess a specified product under laboratory conditions. They do not by themselves establish a human therapeutic benefit, a universally safe product or a human dosing limit.

• The 2025 M2-funded experiment tested specific powders in rat toxicity, bacterial mutation and mouse micronucleus assays (original Methods/Discussion). Its Lion’s Mane material included mycelium, fruiting body and retained oat cultivation material. It did not test human cognition, nerve regeneration or every commercial preparation.
• The mechanism review describes NGF-related cell experiments, including human-derived astrocytoma cells; it also reports inconsistent results for isolated hericenones (cell/constituent discussion). A cultured human cell is not a living human brain, and these review descriptions do not independently verify every underlying original.
• The same review discusses male-mouse stress/depressive-like models and different preparations (preclinical section/Table 1). These are animal endpoints, not a validated human depression treatment.

Human outcomes and adverse-event reports need their own assessment. Nonclinical findings can explain hypotheses but cannot replace clinical benefit or safety evidence.

Funding, conflicts and source roles

Follow the money

Research funding at a glance

Funding & backers→Source & study→Claim & limits

3 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.

No single explicit tier could be mapped. This graphic does not assign a new tier or infer independence.

Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.

Source	Declared support / relationships	Role and remaining limits
Mori 2009	Four authors were Hokuto Corporation-affiliated; the company grew the tested fruiting bodies	The original does not itemise cash funding, a separate conflict statement or product payment terms (published original)
Nagano 2010	Aso Biotech supplied active and placebo cookies; two authors had company affiliations	Cash funding, a separate conflict statement and purchase/donation terms were not identified in the original (published original)
Docherty 2023	Sempera Organics provided investigational products; no additional external funding was declared	Authors declared no conflicts and no company role in design, data collection, interpretation, writing or publication. Payment terms and ultimate backing were not itemised (front/back disclosures)

Other disclosures matter too. Li reports Grape King Bio salary support for five named authors and research materials; six authors have company affiliations. Surendran reports two Beyond Alcohol employees and company publication-fee support, while its front also lists a Clasado affiliation. Saitsu’s original does not identify cash funding, supplier terms or a separate conflict declaration (Li disclosures; Surendran front/back; Saitsu original). These relationships and unknowns inform appraisal; they do not automatically invalidate findings or certify company-free evidence.

Frequently asked questions

Does Lion’s Mane actually cure “brain fog”?

The reviewed studies do not establish a “brain fog cure.” Positive individual tasks coexist with null global scores and unfavourable memory or executive-function findings (Docherty Results; Surendran Results). Small selected populations and multiple endpoints limit generalization.

Is the NGF/nerve-regeneration story real?

NGF and nerve-regeneration explanations remain hypotheses for human benefit (mechanism review). The 49-week pilot’s blood/MRI observations did not establish nerve repair (original Results); the 2025 toxicology assays answer a different question (Methods).

What’s the difference between fruiting body and mycelium products?

Fruiting body and mycelium are different fungal materials. Composition depends on cultivation and processing; mycelium is not always a grain-residue product (composition review; submerged-culture Methods). Mixed fungal materials also differ from extraction with two solvents (fruiting-body extraction). Similar labels do not establish equivalent clinical results.

Is Lion’s Mane safe?

Safety cannot be generalized across products and populations. Mori had mild GI reports in both arms; the 49-week mycelial pilot had three active and one placebo adverse-event withdrawal (Mori; Li). A separate probable severe oral-extract respiratory reaction required intensive care (original case). Selected studies and individual cases cannot quantify every long-term or pregnancy risk.

What dose do the human studies actually use?

Mori used 3 g/day tablets containing 96% fruiting-body powder (2.88 g powder), Nagano 2 g/day powder in cookies, and Docherty 1.8 g/day proprietary complex (Mori; Nagano; Docherty). Other protocols used different materials/durations. These amounts are not a single confirmed effective dose, and no market-wide disclosure rate was measured.

Should I take Lion’s Mane instead of an evidence-based treatment for memory problems or depression?

It should not replace clinical assessment or established treatment. The studies here concern small selected samples, including MCI and mild-AD protocols; neither a within-group score change nor a limited task signal establishes a general memory/depression treatment (Mori; Nagano; Li). Discuss persistent memory or mood concerns with a clinician.

Sources and funding notes

• Mori 2009 — Phytother Res 23:367–372. Modified HDS-R-based MCI trial: 30 randomized, 29 analysed. Hokuto affiliations and company cultivation were reported; cash funding, a separate conflict declaration and supply terms were not itemised. The DOI and PubMed links identify the same trial (DOI).
• Nagano 2010 — Biomed Res 31:231–237. Four-week cookie trial: 30 enrolled, 26 analysed. Total between-group psychometric comparisons were null; exploratory complaint items favoured treatment. Aso Biotech supplied cookies and had author affiliations; other cash funding and supply terms were not itemised.
• Docherty 2023 — Nutrients 15:4842. Proprietary-complex pilot: 43 acute and 41 chronic participants, with mixed exploratory results. Sempera supplied products; no additional external funding or conflicts were declared. Product payment terms were not itemised.
• Mahadevan 2025 — Front Toxicol 7:1651442. Specified powders underwent animal toxicity and bacterial/mouse genotoxicity testing, not human cognition testing. M2 Ingredients funded the study and employed two authors. Methods describe M2 participation in manuscript preparation; the end declaration reports no funder role in preparing the study report. Financial amounts and contract terms were not itemised.
• Chong mechanism review — Int J Mol Sci 2020;21:163, published online in December 2019. Support included the Hong Kong Research Grant Council and HKU Seed Fund 201811160028; no conflicts were declared. This narrative review does not establish the funding of every underlying experiment.
• AESAN 2019 consultation — Novel-food status assessment of dehydrated mycelium powder, based on pre-May 1997 consumption history. This was not a toxicity assessment or evidence of clinical benefit.
• European Commission consultation inventory — Preparation- and process-specific novel-food status records. These are not clinical trials or universal product approval certificates.
• Nakatsugawa 2003 case report — Intern Med 42:1219–1222. Probable ARDS after oral extract use, requiring intensive care. A single case cannot determine frequency or definite causality. Cash funding, a separate conflict declaration and product supply terms were not itemised.
• Saitsu 2019 — Biomed Res 40:125–131. Healthy older adults: 34 randomized, 31 analysed. A small near-ceiling MMSE difference accompanied null results on two other memory tests. Supplier terms, cash funding and a separate conflict declaration were not identified.
• Li 2020 — Front Aging Neurosci 12:155. A 49-week mycelial pilot in mild Alzheimer’s disease: 49 randomized, 41 completed. Final CASI/MMSE between-group differences were null; IADL favoured treatment. Company salary/material support and adverse-event withdrawals were disclosed. The paper title’s “prevention” wording does not establish prevention of Alzheimer’s disease.
• Surendran 2025 — Front Nutr 12:1405796. An 18-person single-dose fruiting-body-extract drink crossover: global cognition and mood were null, with mixed individual task results. Company employment, a separate commercial affiliation and publication-fee support were reported; product payment terms were not itemised.

One daily research roundup

Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.

Email address

Leave empty

I want Pure City Research daily digests and have read the privacy policy.Get the daily digest

Confirm through your inbox. Unsubscribe anytime. Research only; Shop updates have a separate signup. Please do not send health information.